Source disclosure: February 20, 2026
MediciNova,Inc. [4875.T]
TOKYO, Feb 20 (Pulse News Wire) – Medicinova,inc. (4875.T) disclosed its fiscal year 2025 fourth quarter earnings report, more than 50 days after the end of the reporting period.
The delay was attributed to increased regulatory scrutiny and global risks leading to more stringent accounting audits in the United States, necessitating extensive documentation and verification processes. In response to this delay, MediciNova stated it takes the situation seriously and is committed to preventing future occurrences. The company plans to enhance communication with auditors through pre-audit confirmations and additional measures to ensure timely release of future reports within 45 days post-quarter-end.
MediciNova, headquartered in La Jolla, California, focuses on developing bio-pharmaceutical products across various disease areas such as inflammatory conditions, neurodegenerative diseases, and cancer. Key compounds MN-166 (ibudilast) and MN-001 (taprenepag) are currently undergoing Phase III trials for ALS and degenerative cervical myelopathy, while also being tested in Phase II for glioblastoma and substance dependence treatment. Additionally, MN-001 is in Phase II clinical trials targeting lipid abnormalities due to diabetes and non-alcoholic fatty liver disease (NAFLD).
AI-translated content. 🟢 Confidence: High See terms • Original filing